Daihan Pharmaceutical Co.Ltd (023910) — Cash Flow-to-Debt Ratio
Daihan Pharmaceutical Co.Ltd (023910) has a Cash Flow-to-Debt Ratio of 0.19x as of September 2025, meaning its operating cash flow of ₩9.47 Billion could theoretically repay 0% of its total liabilities (₩50.75 Billion) in one year. See 023910 FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Daihan Pharmaceutical Co.Ltd Cash Flow-to-Debt Ratio (2014–2024)
Historical debt coverage capacity for Daihan Pharmaceutical Co.Ltd across 11 annual periods. For the full cash flow conversion analysis, see 023910 operating cash flow.
Annual Cash Flow-to-Debt Ratio for Daihan Pharmaceutical Co.Ltd (2014–2024)
Year-by-year debt coverage analysis for Daihan Pharmaceutical Co.Ltd. Check Daihan Pharmaceutical Co.Ltd earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.74x | ₩35.64 Billion | ₩48.42 Billion | ▼ -12.3% |
| 2023 | 0.84x | ₩38.86 Billion | ₩46.28 Billion | ▲ +49.4% |
| 2022 | 0.56x | ₩29.00 Billion | ₩51.58 Billion | ▼ -3.5% |
| 2021 | 0.58x | ₩40.62 Billion | ₩69.73 Billion | ▲ +23.3% |
| 2020 | 0.47x | ₩33.63 Billion | ₩71.17 Billion | ▲ +7.3% |
| 2019 | 0.44x | ₩35.26 Billion | ₩80.08 Billion | ▼ -7.5% |
| 2018 | 0.48x | ₩44.94 Billion | ₩94.39 Billion | ▲ +59.5% |
| 2017 | 0.30x | ₩20.45 Billion | ₩68.52 Billion | ▼ -28.0% |
| 2016 | 0.41x | ₩27.92 Billion | ₩67.36 Billion | ▲ +43.0% |
| 2015 | 0.29x | ₩17.98 Billion | ₩61.99 Billion | ▲ +106.5% |
| 2014 | 0.14x | ₩9.48 Billion | ₩67.52 Billion | — |